7.
A dropout rate of 20.0% has been anticipated. Has the impact on the integrity of the trial been discussed. 8. Interim analysis when 53% of information obtained -why? 9. Funding source? Role? Not stated. 10. Randomization method not described. Page 7: authors define inclusion criteria to include a predicted genetic risk >10%, defining by those with or without a first degree family history. Perhaps study should be stratified by this risk factor.
REVIEWER
Page 8: Some of the exclusion criteria on pa ge 7 lines 40-47 is a bit subjective and left to the opinon of the investigators…this might lead to bias.
If compliance is an issue in enrollment, this might affect the intent to treat in undesirable ways. There may be something different about those patients deemed non-eligible for reasons related to their poor likelihood to comply.
Care is needed as to what is being estimated and tested and to the assumptions when using the Cox model (proportional hazards assumption). Using site as a covariate may or may not make sense, and it might be better to stratify.
Authors state that they have a pre-specified group sequential procedure for determining significance, but it is not shown. What happens if a threshold is passed earlier in the study?
The authors state that a variety of secondary analysis are planned, but details are omitted. They should be included.
VERSION 1 -AUTHOR RESPONSE
•Reviewer: 1 Reviewer Name: Colin M Dayan
Minor points: 1. Is the genetic risk modified by ethnicity? Are non-caucasians (although relatively rare) excluded?
There are insufficient data on the performance of the genetic risk score in non-Caucasian populations. Our expectation is that the frequency of non-Caucasians who have the Caucasian risk criteria will be lower than that in Caucasians, but the risk will still be high. The protocol committee felt that nonCaucasians should not be excluded if they fulfilled the inclusion criteria and were not excluded for other reasons. We have not modified the manuscript to explicitly state this.
2. Some more detail on GPPAD and how the mothers are consented and a link to GPPAD website should be provided.
We have added this information.
When is consent taken -in GPPAD or again for POINT?
Consent is taken for genetic testing and again for participation in POInT. This information is now added in the consenting paragraph.
4. Explain how more about how blood is taken and blood volume. "3%".
The information was added to the text and suppl file 1. In addition a reference was added referring to blood volume in previous studies.
Explain terms in figure 1 pBL, call 1 call 2
Information on pBL (post baseline visit) and interim telephone calls have been added.
6. Why is vitamin D measured but not treated in a standardised fashion (but "according to local guidelines" We did not want to introduce supplementation as part of the protocol intervention, but wanted to support attention to vitamin D sufficiency and supplementation in childhood. The protocol committee decided that because the primary care is provided by local physicians with local guidelines, it was appropriate to bring it to their attention and have them encourage supplementation. We actually have a standard recommendation, which is to increase supplementation to 1000 IU/day. The wording of this has been revised.
7.
A dropout rate of 20.0% has been anticipated. Has the impact on the integrity of the trial been discussed.
The dropout rate has been considered for the power calculation. Dropouts will be compared to the remainder of participants to establish bias as is typically performed in long clinical trials.
Interim analysis when 53% of information obtained -why?
It is more than 50% of the expected events, which is expected at around 4.5 years. We have now revised it and include decision guidelines for the interim analysis.
9. Funding source? Role? Not stated.
This is now added to the manuscript 10. Randomization method not described.
This is now added (page 8). We have added the references to the text and table.
Page 6 line 55: autors state 1040 infants will be enrolled and randomized. Is there power/sample size considerations that give rise to this? There is a study power and accrual target section later in the text, but this is not described clearly. What hazard ratio are they assuming for the calculation? If they are using a logrank test based on a Cox model, this is what they should be powering for. It doesn't sound like this is well thought out.
The sample size estimate is given in the Analysis section. This HR is now included as is the programme that was used to estimate the sample size numbers.
Page 7: authors define inclusion criteria to include a predicted genetic risk >10%, defining by those with or without a first degree family history. Perhaps study should be stratified by this risk factor.
There is no evidence for a different timing or initiation between general population and first degree relative children. FDR status is a covariate (this has been revised in the protocol). Secondary analyses will include stratification by FDR status (now stated in the manuscript).
Page 8: Some of the exclusion criteria on pa ge 7 lines 40-47 is a bit subjective and left to the opinon of the investigators…this might lead to bias. This is correct and we are aware of the potential bias. We have a recruitment committee that is consulted on such exclusion criteria to reduce subjectivity and bias. We have not added this information to the manuscript.
As mentioned above, these cases are reviewed centrally and discussed. Our experience is that very few cases are excluded by this criteria.
The reviewer is correct. The primary analysis will not stratify by site since we do not expect large site differences in the primary outcome rate in the participants who have been selected on risk criteria and, as referred to by the reviewer, we expect imbalance in the number of participants at each site. Indeed site has since been omitted as a covariate in the study analysis plan.
